According to Acorda Therapeutics, Biopas Laboratories has submitted marketing applications for Inbrija levodopa inhalation powder for the treatment of OFF episodes in Parkinson’s disease in Argentina, Colombia, Costa Rica, Ecuador, Panama, and Peru. In May 2022, Biopas acquired the rights to Inbrija in those 6 countries, plus Brazil, Chile, and Mexico. Acorda says that Biopas plans a submission for Inbrija in Chile later this year and submissions in Brazil and Mexico in 2024.
Inbrija was approved by the FDA in December 2018 and was launched in the US by Acorda in February 2019. In Europe, Inbrija was approved in 2019 and has been launched in Germany and Spain by Esteve. Chance Pharmaceuticals acquired the Chinese rights to the DPI earlier this year. Catalent acquired the facility that manufactures Inbrija from Acorda in 2021 and signed a new supply agreement with Acorda in January 2023.
Acorda President and CEO Ron Cohen commented, “We are delighted that Biopas has submitted filings for the approval of Inbrija in six countries in Latin America, with up to five approvals expected in 2024. This is an important step forward for those living with Parkinson’s in these countries. Biopas is a leader in commercializing CNS therapies in Latin America, and we thank them for their commitment to ensuring further access to our important medication.”
Read the Acorda Therapeutics press release.
